Infliximab

Caesarean

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S4896
R12935
Broms (Controls exposed to other treatments), 2020 Caesarean section 3 months (or more) before pregnancy or during pregnancy population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 2.38 [1.80;3.13] C
excluded (control group)
98/208   2,560/9,393 2,658 208
ref
S4897
R12940
Broms (Controls unexposed, disease free), 2020 Caesarean section 3 months (or more) before pregnancy or during pregnancy excluded population based cohort retrospective unexposed, disease free Adjustment: No 4.24 [3.23;5.57] C
excluded (exposition period)
98/208   281,654/1,623,483 281,752 208
ref
S4966
R13040
De Lorenzo (Controls unexposed, disease free), 2020 Caesarean at least 1st trimester retrospective cohort unexposed, disease free excluded Adjustment: No 16.18 [0.71;370.88] C
excluded (control group)
3/3   9/36 12 3
ref
S4967
R13046
De Lorenzo (Controls unexposed, sick), 2020 Caesarean at least 1st trimester excluded retrospective cohort unexposed, sick Adjustment: No 7.80 [0.34;176.35] C
excluded (exposition period)
3/3   13/32 16 3
ref
Total 0 studies NaN [NaN;NaN] 0 0
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

Sensitivity analysis